Quantcast

Latest Cystic fibrosis Stories

2014-03-12 08:29:44

BOULDER, Colo., March 12, 2014 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma") announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF). In preclinical studies, N91115 has been shown to rescue or "correct" F508del-CFTR, the most commonly occurring mutation in CF. It is the first oral GSNOR inhibitor to enter clinical...

2014-03-10 16:32:54

BioCentury Conference Presentation to be Webcast SOUTH SAN FRANCISCO, Calif., March 10, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conferences: -- 26(th) Annual ROTH ConferenceWednesday, March 12, 2014 in Laguna Niguel, California8:00 - 8:30 AM Pacific Time -- BioCentury's Future Leaders in the Biotech Industry ConferenceFriday, March 28, 2014 in New...

2014-03-04 23:28:30

Ray Scardigno, the President of FiltersFast.com will participate in the Cystic Fibrosis Foundation “Xtreme Hike for a Cure” in an effort to raise money for a cure for cystic fibrosis on April 26, 2014. In support of this effort, FiltersFast.com will match all donations up to $7,500. Charlotte, NC (PRWEB) March 04, 2014 Ray Scardigno, the President of FiltersFast.com is giving back to the community by participating in the Cystic Fibrosis Foundation “Xtreme Hike for a Cure” on April...

2014-02-25 08:32:43

ALBANY, New York, February 25, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Pulmonary Drug Delivery Systems Market(Products- Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications- Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global pulmonary drug delivery systems market was valued at USD 21.03billion in 2012 and is expected to grow...

2014-02-24 23:20:43

New research report “Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth” worked out by GBI Research is now available at MarketPublishers.com. According to the study, the combined value of the cystic fibrosis (CF) markets in the top 8 developed economies is set to grow at a 30.4% CAGR through 2019. London, UK (PRWEB) February 24, 2014 In 2012, the combined value of the cystic fibrosis (CF)...

Cystic Fibrosis Flare-ups May Be Caused By Buttery Molecule Diacetyl
2014-02-24 06:52:58

By Michael Price, San Diego State University Katrine Whiteson and colleagues identified a lung-damaging molecule in higher concentrations in cystic fibrosis patients during symptom flare-ups. A molecule previously linked to lung injuries in factory workers producing microwave popcorn might play an important role in microbial infections of the lung suffered by people with cystic fibrosis (CF), according to a recent study led by San Diego State University postdoctoral researcher Katrine...

2014-02-19 08:31:18

SAN DIEGO, Feb. 19, 2014 /PRNewswire/ -- CURx Pharmaceuticals today announced it has entered into a global license agreement with Gilead Sciences, Inc. for development of Fosfomycin:Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients. FTI is ready for Phase III clinical trials, having successfully completed a Phase II trial in CF patients. (Logo: http://photos.prnewswire.com/prnh/20140212/MM64137LOGO) "This is a great...

2014-02-18 04:20:49

ALBANY, New York, February 18, 2014 /PRNewswire/ -- MarketResearchReports.Biz includes new market research report " Cystic Fibrosis Therapeutics In Major Developed Markets To 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment And Market Growth" to its large collection of research reports....

2014-02-10 16:26:36

Successes in cystic fibrosis care delivery and drug development serve as a model for policymakers and greater rare disease community BETHESDA, Md., Feb. 10, 2014 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation will host a briefing on Capitol Hill to highlight how care delivery and drug development models in cystic fibrosis are an example for health policy experts seeking new ways to treat rare diseases and accelerate drug development. The panel discussion, "Personalized Medicine...

2014-02-10 08:27:53

Study Aims To Evaluate Improvement in Lung Function after Treatment with NOxCureCF REHOVOT, Israel, February 10, 2014 /PRNewswire/ -- Advanced Inhalation Therapies (AIT Ltd.), a drug development company, announced today it added Schneider Children's Medical Center of Israel as the second site in its multicenter, open-label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis (CF). Schneider Children's is the largest children's...


Latest Cystic fibrosis Reference Libraries

Cystic Fibrosis
2013-07-19 15:03:45

Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...

More Articles (1 articles) »
Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related